What is the story about?
What's Happening?
Jyong Biotech Ltd., a Taiwan-based biotechnology company, has been awarded the Innovation Gold Award in the Pharmaceutical Category at the 2025 Taipei Biotech Awards. The award was given for the development of BOTRESO®, an oral plant-derived investigational new drug aimed at treating benign prostatic hyperplasia and lower urinary tract syndrome. BOTRESO® has completed four Phase III clinical trials in the United States and Taiwan and is the first Taiwan-developed oral botanical drug to receive U.S. FDA Investigational New Drug approval. The award, presented by Taipei City Mayor Wayne Chiang, recognizes Jyong Biotech's achievements in innovation and cross-disciplinary excellence.
Why It's Important?
The recognition of Jyong Biotech's BOTRESO® highlights the growing importance of plant-derived pharmaceuticals in the global healthcare market. This award not only validates the company's research and development efforts but also underscores the potential of botanical drugs to address unmet medical needs. The U.S. market, being a primary focus for Jyong Biotech, stands to benefit from innovative treatments for urinary system diseases. The success of BOTRESO® could pave the way for more plant-based therapies, potentially reducing reliance on synthetic drugs and offering new options for patients.
What's Next?
Following the award, Jyong Biotech is expected to continue its efforts to expand its global presence, particularly in the U.S. and EU markets. The company has submitted a New Drug Application to the U.S. FDA, and approval could lead to the commercialization of BOTRESO® in the U.S. market. This development may attract attention from investors and partners interested in botanical drug innovation, potentially leading to collaborations or further investment in the company's pipeline.
AI Generated Content
Do you find this article useful?
